Thank you, Tina, and good morning, everyone. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and other filings from today that are available on our Investor website at I will now turn the call over to Tim. In addition, on today’s conference call, non-GAAP financial measures will be used. You are cautioned not to place undue reliance on these forward-looking statements, and Horizon disclaims any obligation to update such statements. These statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2018, subsequent quarterly reports on Form 10-Quarter, and our earnings press release, which we issued this morning. We’ll then take your questions.Īs a reminder, during today’s call, we’ll be making certain forward-looking statements, including statements about financial projections, our business strategy and the expected timing and impact of future events. Shao-Lee will provide a review of our R&D programs, and Paul will discuss our financial performance and guidance, followed by closing remarks from Tim. He will also discuss in greater detail our prelaunch preparations for teprotumumab, our first-in-class biologic under FDA review for thyroid eye disease or TED. Tim will provide a high level review of the third quarter and an update on our business. On the call with me today are Tim Walbert, Chairman, President and Chief Executive Officer Shao-Lee Lin, Executive Vice President, Head of Research and Development and Chief Scientific Officer Paul Hoelscher, Executive Vice President, Chief Financial Officer Vikram Karnani, Executive Vice President, Chief Commercial Officer and Andy Pasternak, Executive Vice President, Chief Business Officer. Good morning, everyone, and thank you for joining us. Tina Ventura, Senior Vice President of Investor Relations. As a reminder, today’s conference is being recorded. Welcome to Horizon Therapeutics’ PLC Third Quarter 2019 Earnings Conference Call. Good morning and thank you for standing by. Vikram Karnani - EVP and Chief Commercial OfficerĪndy Pasternak - EVP Chief Business Officer Shao-Lee Lin - EVP, Head, R&D and Chief Scientific Officer Tim Walbert - Chairman, President and CEO Insider trading is most common in January, with the busiest year in 2021.Horizon Therapeutics plc ( NASDAQ: HZNP) Q3 2019 Results Conference Call Novem8:00 AM ET In the last 12 years, insiders at Horizon Therapeutics Public Ltd Co have sold an estimated value of $967.93MĪnd bought an estimated value of $122.97M worth of shares. Horizon Therapeutics Public Ltd Co's most recent insider trade came on JanubyĪndy Pasternak who sold 27,129 units worth Source: What are Horizon Therapeutics Public Ltd Co's Past Insider Trades? Other earnings, plans or compensations of $75,659. Other earnings, plans or compensations of $75,659, and Other earnings, plans or compensations of $75,659 , The vast majority of their compensation came in the form of īarry Moze received compensation valued at about $5,073,877 in 2020 after becoming EVP. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.Īs EVP of Horizon Therapeutics Public Ltd Co, Barry Moze has a total base salary of $628,960. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |